Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression

Summary & key facts

This paper reviews how ketamine helps people with treatment-resistant depression. It says ketamine blocks NMDA receptors, which raises glutamate in brain areas tied to mood. The drug can work quickly and is described as having a positive safety profile. But results differ a lot between people. Factors like how ketamine is given, the dose and delivery speed, past trauma, and genetics may affect who benefits. The authors recommend more research and explore combining ketamine with therapies such as CBT and mindfulness.

Key facts:

• Ketamine acts as an NMDA receptor antagonist, which leads to increased glutamate in brain regions involved in mood regulation.
• The paper reports that ketamine can promote synaptic plasticity and neurogenesis, which may counteract effects of chronic stress.
• Ketamine is described in the paper as having an acute (fast) onset of antidepressant action and a positive safety profile.
• Response to ketamine varies among individuals; the paper highlights route of administration, dose, and rate of delivery as factors that can influence efficacy.
• The authors note that non-drug factors such as past traumatic experiences and genetic predispositions may also affect how well someone responds to ketamine.
• The paper identifies growing interest in combining ketamine with psychotherapies, including Cognitive Behavioural Therapy (CBT) and Mindfulness-Based Interventions (MBIs), and calls for further research to tailor treatments.

Abstract

Ketamine, often associated with its frequent illicit recreational use, is renowned as an approved alternative for treatment-resistant depression. This paper evaluates the mechanism of ketamine’s role in treating depression, emphasising its positive safety profile and acute onset of action. Ketamine’s mechanism of action involves antagonism of N-methyl-D-Aspartate (NMDA) receptors, leading to increased glutamate production in brain regions associated with mood regulation. Moreover, ketamine counteracts the effects of chronic stress by promoting synaptic plasticity and neurogenesis. However, the response to ketamine varies among individuals, prompting the need for further investigation into the factors influencing its efficacy, such as route of administration, dose and the rate at which it is delivered. Other variables such as past traumatic experiences and genetic predispositions may also play a significant role in determining an individual’s response to ketamine therapy, raising the importance of tailored treatment approaches. Furthermore, there is growing interest in investigating the synergy of ketamine alongside other therapeutic modalities, including Cognitive Behavioural Therapy (CBT) and Mindfulness-Based Interventions (MBIs), as a means to enhance treatment outcomes in modern psychiatry.

Topics

Mental Health Research Topics Treatment of Major Depression Tryptophan and brain disorders

Categories

Health Sciences Medicine Pharmacology

Tags

Cognition Depression (economics) Economics Ketamine Macroeconomics Major depressive disorder Medicine Psychiatry Psychology Treatment-resistant depression

Substances

Ketamine

Conditions & symptoms

Depression Sadness or low mood